Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

Next Previous
Trial Profile

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IAM 1363 (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Brain metastases; Cancer; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Iambic Therapeutics

Most Recent Events

  • 16 Dec 2025 According to an Iambic Therapeutics media release, data from this study will be presented at the 44th Annual J.P. Morgan Healthcare Conference. Iambic's presentation will take place on Tuesday, January 13, 2026, at 4:30 p.m. PT at the Westin St. Francis Hotel in San Francisco.
  • 21 Oct 2025 According to an Iambic Therapeutics media release, company announced a research collaboration and drug supply agreement with Jazz Pharmaceuticals. Under the agreement, Jazz will provide zanidatamab (Ziihera) for evaluation in combination with IAM1363a and capecitabine, the combination will be studied in the phase I/Ib IAM1363-01 study.
  • 20 Oct 2025 Results presented in the Iambic Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top